Cancer immune evasion is recognized as a central hallmark of tumor development, and targeting programmed death receptor 1 (PD-1)/programmed death ligand 1 (PD-L1) to restore the normal anti-tumor immune response has been difficult (Mortezaee, 2020). This evidence concerns the gene CD274 and neoplasm.